Top

Journal of Gastrointestinal Cancer

Published in:

01-03-2020 | Original Research

MAEL Cancer-Testis Antigen as a Diagnostic Marker in Primary Stages of Gastric Cancer with Helicobacter pylori Infection

Authors: Mohammad Reza Abbaszadegan, Negin Taghehchian, Azadeh Aarabi, Meysam Moghbeli

Published in: Journal of Gastrointestinal Cancer | Issue 1/2020

Abstract

Purpose

Gastric cancer (GC) is the third leading cause of cancer related deaths in the world. Cancer testis antigens (CTAs) are involved in tumor progression of various cancers. These markers have not any expression or minimally expression in normal tissues, highlighting them as efficient methods for molecular targeted therapy. In the present study, we assessed the role of MAEL as a CTA in biology of GC and risk of Helicobacter Pylori (H pylori) infection.

Methods

Levels of MAEL mRNA expression in 80 GC tumor tissues were compared to their corresponding normal margins using the real-time polymerase chain reaction.

Results

There was a significant correlation between MAEL expression and tumor stage (p = 0.050). There were also significant correlations between MAEL expression and tumor grade (p = 0.015) and depth of invasion (p = 0.030) among the H pylori negative cases.

Conclusions

MAEL is probably associated with aggressiveness of primary-stage tumors and can be introduced as an efficient marker for the early detection and also H pylori infected tumors in GC patients.

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108. https://doi.org/10.3322/caac.21262.CrossRef

Mousavi SM, Gouya MM, Ramazani R, Davanlou M, Hajsadeghi N, Seddighi Z. Cancer incidence and mortality in Iran. Ann Oncol. 2009;20(3):556–63. https://doi.org/10.1093/annonc/mdn642.CrossRefPubMed

Ahmad SA, Xia BT, Bailey CE, Abbott DE, Helmink BA, Daly MC, et al. An update on gastric cancer. Curr Probl Surg. 2016;53(10):449–90. https://doi.org/10.1067/j.cpsurg.2016.08.001.CrossRefPubMed

Rocken C. Molecular classification of gastric cancer. Expert Rev Mol Diagn. 2017;17(3):293–301. https://doi.org/10.1080/14737159.2017.1286985.CrossRefPubMed

Zhang D, Xiong H, Shan J, Xia X, Trudeau VL. Functional insight into maelstrom in the germline piRNA pathway: a unique domain homologous to the DnaQ-H 3′-5′ exonuclease, its lineage-specific expansion/loss and evolutionarily active site switch. Biol Direct. 2008;3:48. https://doi.org/10.1186/1745-6150-3-48.CrossRefPubMedPubMedCentral

Lim SL, Ricciardelli C, Oehler MK, Tan IM, Russell D, Grutzner F. Overexpression of piRNA pathway genes in epithelial ovarian cancer. PLoS One. 2014;9(6):e99687. https://doi.org/10.1371/journal.pone.0099687.CrossRefPubMedPubMedCentral

Kim YH, Lee HC, Kim SY, Yeom YI, Ryu KJ, Min BH, et al. Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann Surg Oncol. 2011;18(8):2338–47. https://doi.org/10.1245/s10434-011-1573-y.CrossRefPubMedPubMedCentral

Liu L, Dai Y, Chen J, Zeng T, Li Y, Chen L, et al. Maelstrom promotes hepatocellular carcinoma metastasis by inducing epithelial-mesenchymal transition by way of Akt/GSK-3beta/Snail signaling. Hepatology. 2014;59(2):531–43. https://doi.org/10.1002/hep.26677.CrossRefPubMed

Brennecke J, Malone CD, Aravin AA, Sachidanandam R, Stark A, Hannon GJ. An epigenetic role for maternally inherited piRNAs in transposon silencing. Science. 2008;322(5906):1387–92. https://doi.org/10.1126/science.1165171.CrossRefPubMedPubMedCentral

10.

Malone CD, Hannon GJ. Small RNAs as guardians of the genome. Cell. 2009;136(4):656–68. https://doi.org/10.1016/j.cell.2009.01.045.CrossRefPubMedPubMedCentral

11.

Raeisossadati R, Abbaszadegan MR, Moghbeli M, Tavassoli A, Kihara AH, Forghanifard MM. Aberrant expression of DPPA2 and HIWI genes in colorectal cancer and their impacts on poor prognosis. Tumour Biol. 2014;35(6):5299–305. https://doi.org/10.1007/s13277-014-1690-x.CrossRefPubMed

12.

Xiao L, Wang Y, Zhou Y, Sun Y, Sun W, Wang L, et al. Identification of a novel human cancer/testis gene MAEL that is regulated by DNA methylation. Mol Biol Rep. 2010;37(5):2355–60. https://doi.org/10.1007/s11033-009-9741-x.CrossRefPubMed

13.

Kim SH, Park ER, Cho E, Jung WH, Jeon JY, Joo HY, et al. Mael is essential for cancer cell survival and tumorigenesis through protection of genetic integrity. Oncotarget. 2017;8(3):5026–37. https://doi.org/10.18632/oncotarget.13756.CrossRefPubMed

14.

Yuan L, Xiao Y, Zhou Q, Yuan D, Wu B, Chen G, et al. Proteomic analysis reveals that MAEL, a component of nuage, interacts with stress granule proteins in cancer cells. Oncol Rep. 2014;31(1):342–50. https://doi.org/10.3892/or.2013.2836.CrossRefPubMed

15.

Li XD, Zhang JX, Jiang LJ, Wang FW, Liu LL, Liao YJ, et al. Overexpression of maelstrom promotes bladder urothelial carcinoma cell aggressiveness by epigenetically downregulating MTSS1 through DNMT3B. Oncogene. 2016;35(49):6281–92. https://doi.org/10.1038/onc.2016.165.CrossRefPubMed

16.

Barooei R, Mahmoudian RA, Abbaszadegan MR, Mansouri A, Gholamin M. Evaluation of thymic stromal lymphopoietin (TSLP) and its correlation with lymphatic metastasis in human gastric cancer. Med Oncol. 2015;32(8):217.CrossRef

17.

Polyak K. Heterogeneity in breast cancer. J Clin Invest. 2011;121(10):3786–8. https://doi.org/10.1172/JCI60534.CrossRefPubMedPubMedCentral

18.

Moghbeli M, Forghanifard MM, Aarabi A, Mansourian A, Abbaszadegan MR. Clinicopathological sex- related relevance of musashi1 mRNA expression in esophageal squamous cell carcinoma patients. Pathol Oncol Res. 2014;20(2):427–33. https://doi.org/10.1007/s12253-013-9712-3.CrossRefPubMed

19.

Moghbeli M, Forghanifard MM, Sadrizadeh A, Mozaffari HM, Golmakani E, Abbaszadegan MR. Role of Msi1 and MAML1 in regulation of notch signaling pathway in patients with esophageal squamous cell carcinoma. J Gastrointest Cancer. 2015;46(4):365–9. https://doi.org/10.1007/s12029-015-9753-9.CrossRefPubMed

20.

Moghbeli M, Sadrizadeh A, Forghanifard MM, Mozaffari HM, Golmakani E, Abbaszadegan MR. Role of Msi1 and PYGO2 in esophageal squamous cell carcinoma depth of invasion. J Cell Commun Signal. 2016;10(1):49–53. https://doi.org/10.1007/s12079-015-0314-6.CrossRefPubMed

21.

Taleb S, Abbaszadegan MR, Moghbeli M, Roudbari NH, Forghanifard MM. HES1 as an independent prognostic marker in esophageal squamous cell carcinoma. J Gastrointest Cancer. 2014;45(4):466–71. https://doi.org/10.1007/s12029-014-9648-1.CrossRefPubMed

22.

Li Q, Wei P, Huang B, Xu Y, Li X, Li Y, et al. MAEL expression links epithelial-mesenchymal transition and stem cell properties in colorectal cancer. Int J Cancer. 2016;139(11):2502–11. https://doi.org/10.1002/ijc.30388.CrossRefPubMed

23.

Zhang X, Ning Y, Xiao Y, Duan H, Qu G, Liu X, et al. MAEL contributes to gastric cancer progression by promoting ILKAP degradation. Oncotarget. 2017;8(69):113331–44. https://doi.org/10.18632/oncotarget.22970.CrossRefPubMedPubMedCentral

24.

Costa Y, Speed RM, Gautier P, Semple CA, Maratou K, Turner JM, et al. Mouse MAELSTROM: the link between meiotic silencing of unsynapsed chromatin and microRNA pathway? Hum Mol Genet. 2006;15(15):2324–34. https://doi.org/10.1093/hmg/ddl158.CrossRefPubMed

25.

Fukuyama T, Futawatari N, Ichiki Y, Shida A, Yamazaki T, Nishi Y, et al. Correlation between expression of the cancer/testis antigen KK-LC-1 and Helicobacter pylori infection in gastric cancer. In Vivo. 2017;31(3):403–7. https://doi.org/10.21873/invivo.11073.CrossRefPubMedPubMedCentral

26.

Fukuyama T, Yamazaki T, Fujita T, Uematsu T, Ichiki Y, Kaneko H, et al. Helicobacter pylori, a carcinogen, induces the expression of melanoma antigen-encoding gene (mage)-A3, a cancer/testis antigen. Tumour Biol. 2012;33(6):1881–7. https://doi.org/10.1007/s13277-012-0448-6.CrossRefPubMed

Title: MAEL Cancer-Testis Antigen as a Diagnostic Marker in Primary Stages of Gastric Cancer with Helicobacter pylori Infection
Authors: Mohammad Reza Abbaszadegan
Negin Taghehchian
Azadeh Aarabi
Meysam Moghbeli
Publication date: 01-03-2020
Publisher: Springer US
Published in: Journal of Gastrointestinal Cancer / Issue 1/2020
Print ISSN: 1941-6628
Electronic ISSN: 1941-6636
DOI: https://doi.org/10.1007/s12029-018-0183-3

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Computerized Tomography Criteria as a Tool for Simplifying the Assessment of Locally Advanced Rectal Cancer

Locally Advanced Rectal Cancer Evaluation by Magnetic Resonance Imaging after Neoadjuvant Therapy on Decision Making: Cancer Center Experience and Literature Review

Pancreatic Malignant Gastrointestinal Stromal Tumor: a Case Report

Dilemmas in Diagnosis and Management of Gastroenteropancreatic Mixed Neuroendocrine Non-neuroendocrine Neoplasms: First Single-Centre Report from India

Association of High Expression Levels of SOX2, NANOG, and OCT4 in Gastric Cancer Tumor Tissues with Progression and Poor Prognosis

Are We Choosing Surveillance Imaging in Gastric and Pancreatic Cancers Wisely? A Population-Based Study

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials